Comparison of Short Duration Levetiracetam to Extended Course Levetiracetam for Seizure Prophylaxis Following Subarachnoid Hemorrhage
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 84
- 试验地点
- 2
- 主要终点
- In-hospital Seizures
研究概览
简要总结
Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital seizures when compared to an extended course.
详细描述
This is a prospective, single-center, randomized, controlled trial. Patients admitted with spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam 1000 mg twice daily for 3 days or levetiracetam 1000mg twice daily until hospital discharge.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >18 years of age
- •Diagnosis of spontaneous SAH
排除标准
- •SAH secondary to trauma or arteriovenous malformation
- •Early death (defined as death within 3 days of presentation)
- •Known allergy to levetiracetam
- •Know seizure history on chronic AEDs
- •Current incarceration
研究组 & 干预措施
Brief LEV
Administration of three days of levetiracetam twice daily after SAH
干预措施: Brief LEV (Other)
Extended LEV
Administration of levetiracetam twice daily after SAH
干预措施: Extended LEV (Other)
结局指标
主要结局
In-hospital Seizures
时间窗: from hospital admission to hospital discharge
from admission to In-hospital seizures after aSAH
次要结局
未报告次要终点
研究者
Theresa Human-Murphy
Dr.
Washington University School of Medicine